原发性和转移性肾细胞癌中前列腺特异性膜抗原（PSMA）的表达（UroCCR - 65研究）

Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study).

作者信息

Binzaqr Salma, Kryza David, Giraudet Anne-Laure, Bernhard Jean Christophe, Gross-Goupil Marine, Yacoub Mokrane, Margue Gaelle, Hindié Elif, Morgat Clément

机构信息

Department of Nuclear Medicine, University Hospital of Bordeaux, Bordeaux, F-33076, France.

Univ. Lyon - Université Claude Bernard Lyon 1, LAGEPP UMR 5007 CNRS, Villeurbanne, F-69100, France.

出版信息

EJNMMI Res. 2025 Apr 9;15(1):38. doi: 10.1186/s13550-025-01232-8.

DOI:10.1186/s13550-025-01232-8

PMID:40205264

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11981970/

Abstract

BACKGROUND

Prostate-specific membrane antigen (PSMA) has been shown to be overexpressed in the neo-vasculature of renal cancers. However, studies investigating the pattern of PSMA expression in primary RCC and RCC metastases according to metastatic sites are rare. 44 frozen samples of RCC, 19 primaries (9 clear cell (cc) RCC, 7 papillary (pap) RCC, and 3 chromophobe (ch) RCC) and 25 (24 samples have ccRCC histology and one is unclassified) unpaired metastases (8 from adrenals, 8 from bones, 2 from lungs, 2 from liver and 5 others (1 lymph node, 1 pancreas, 1 brain, 1 gallbladder and 1 muscle)), were available from the UroCCR project (NCT03293563). PSMA expression was assessed by autoradiography using [Lu]Lu-PSMA-617 as binding agent and the specific binding (total binding-non-specific binding) was calculated and expressed as a percentage of total binding. A patient suffering from metastatic ccRCC was also administered [Ga]Ga-PSMA-11 to evaluate PSMA expression.

RESULTS

The mean specific binding was 28.9 ± 40.4% for primary renal cancer and 65.0 ± 38.9% for metastasis. Regarding histology, high PSMA expression was depicted in 33.3% of ccRCC, 33.3% of chRCC and 57.1% of papRCC. PSMA was more frequently expressed in primary samples of papRCC histology with renal capsule invasion (p = 0.0286). A higher PSMA-specific binding and a higher number of samples with high PSMA-expression were depicted in metastatic samples. Bone metastasis showed lower binding than other metastatic sites combined (p = 0.0005). The patient suffering from metastatic ccRCC showed high [Ga]Ga-PSMA-11 uptake on known distant metastases and additional site uncovered.

CONCLUSION

PSMA showed high expression in metastases of ccRCC.

CLINICAL TRIAL REGISTRATION

NCT, NCT03293563, prospectively registered September 20, 2017, http://www.

CLINICALTRIALS

gov .

摘要

背景

前列腺特异性膜抗原（PSMA）已被证明在肾癌的新生血管中过表达。然而，根据转移部位研究PSMA在原发性肾细胞癌（RCC）和RCC转移灶中表达模式的研究很少。来自UroCCR项目（NCT03293563）的44份RCC冷冻样本，包括19份原发性样本（9份透明细胞（cc）RCC、7份乳头状（pap）RCC和3份嫌色细胞（ch）RCC）以及25份未配对转移灶样本（24份样本为ccRCC组织学类型，1份未分类）（8份来自肾上腺、8份来自骨骼、2份来自肺、2份来自肝脏以及5份其他部位（1份淋巴结、1份胰腺、1份脑、1份胆囊和1份肌肉））。使用[Lu]Lu-PSMA-617作为结合剂通过放射自显影评估PSMA表达，并计算特异性结合（总结合 - 非特异性结合）并表示为总结合的百分比。一名转移性ccRCC患者也接受了[Ga]Ga-PSMA-11以评估PSMA表达。

结果

原发性肾癌的平均特异性结合为28.9±40.4%，转移灶为65.0±38.9%。在组织学方面，33.3%的ccRCC、33.3%的chRCC和57.1%的papRCC表现出高PSMA表达。PSMA在伴有肾包膜侵犯的papRCC组织学原发性样本中更频繁表达（p = 0.0286）。在转移样本中观察到更高的PSMA特异性结合以及更多高PSMA表达的样本。骨转移显示出比其他转移部位总和更低的结合（p = 0.0005）。患有转移性ccRCC的患者在已知远处转移灶和新发现的部位显示出高[Ga]Ga-PSMA-11摄取。